Korro Bio (NASDAQ:KRRO) COO Sells $34,309.44 in Stock

Posted by George Bondi on Jun 17th, 2026

Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) COO Todd Chappell sold 3,168 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $10.83, for a total transaction of $34,309.44. Following the transaction, the chief operating officer owned 16,964 shares of the company’s stock, valued at $183,720.12. This trade represents a 15.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Korro Bio Stock Up 3.7%

Shares of NASDAQ:KRRO traded up $0.39 during trading on Wednesday, hitting $11.05. 143,415 shares of the company were exchanged, compared to its average volume of 194,060. The business’s 50 day moving average is $12.24 and its 200-day moving average is $10.83. The company has a market capitalization of $159.37 million, a P/E ratio of -0.95 and a beta of 3.01. Korro Bio, Inc. has a 1-year low of $5.20 and a 1-year high of $55.89.

Korro Bio (NASDAQ:KRRO – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Korro Bio had a negative return on equity of 117.86% and a negative net margin of 1,834.48%. As a group, sell-side analysts anticipate that Korro Bio, Inc. will post -5.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on KRRO. Raymond James Financial upgraded shares of Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 price target for the company in a report on Friday, March 13th. Wall Street Zen raised shares of Korro Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Cantor Fitzgerald boosted their price objective on shares of Korro Bio from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Friday, March 13th. Lifesci Capital raised shares of Korro Bio to a “strong-buy” rating in a research note on Friday, May 29th. Finally, Clear Str raised shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 18th. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.71.

Read Our Latest Stock Report on KRRO

Institutional Trading of Korro Bio

Several institutional investors have recently modified their holdings of KRRO. Russell Investments Group Ltd. bought a new stake in shares of Korro Bio in the third quarter worth $39,000. Wells Fargo & Company MN grew its stake in shares of Korro Bio by 45.5% in the fourth quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock worth $60,000 after purchasing an additional 2,352 shares during the last quarter. Guggenheim Capital LLC bought a new stake in Korro Bio during the fourth quarter valued at $84,000. Jain Global LLC bought a new stake in Korro Bio during the fourth quarter valued at $85,000. Finally, Deutsche Bank AG boosted its position in Korro Bio by 241.9% during the fourth quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock valued at $102,000 after acquiring an additional 9,027 shares during the last quarter. Institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

(Get Free Report)

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.